Table 5.
Outcome of HCV-associated diffuse large B-cell lymphoma according to the type of treatment.
| Reference | Study design | No. of patients | Treatment | Outcomes | |
|---|---|---|---|---|---|
| Tomita et al. [2003]* | retrospective | 25* | CHOP/CHOP-like | 5-year OS 46% | - |
| Besson et al. [2006] | retrospective | 26 | intensive chemotherapy | 3-year OS 56% | 3-year EFS 53% |
| Visco et al. [2006] | retrospective | 156 | R-CHOP(35)/CHOP or CHOP-like | 3-year OS 72% | 3-year PFS 51% |
| Park et al. [2008] | retrospective | 32 | R-CHOP(11)/CHOP | 5-year OS 59% | 55% (5 year) |
| Ennishi et al. [2010] | retrospective | 131 | R-CHOP | 3-year OS 75% | 3-year PFS 69% |
| Merli et al. [2014] | retrospective | 535 | R-CHOP(255)/CHOP | 3-year OS 71% (71% R-CHOP) | 3-year PFS 55% (58% R-CHOP) |
| Michot et al. [2015]§ | prospective | 27$ | R-CHOP/R-ACVBP | 2-year OS 81% | 2-year PFS 80% |
| Chen et al. [2015] | retrospective | R-CHOP/R-CHOP-like | 3-year OS 55% | 3-year PFS 52% | |
The working formulation was used to define histology by Tomita, who reports 20 large cell lymphomas and other aggressive histological types (including four cases of T-cell non-Hodgkin’s lymphoma).
The analysis of survival was restricted only to the patients prospectively enrolled in the study by Michot.
CHOP, cyclophosphamide, vincristine, prednisone, doxorubicin; EFS, event-free survival; n.r., not reported; OS, overall survival; PFS, progression-free survival; R-ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone plus rituximab; R-CHOP, cyclophosphamide, vincristine, prednisone, doxorubicin plus rituximab; RFS, relapse-free survival.